resTORbio, Inc. (TORC)
Market Cap | 83.11M |
Revenue (ttm) | n/a |
Net Income (ttm) | -65.98M |
Shares Out | 36.45M |
EPS (ttm) | -1.81 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Dividend Yield | n/a |
Trading Day | Sep 16, 2020 |
Last Price | $15.40 |
Previous Close | $2.28 |
Change ($) | 13.12 |
Change (%) | 575.44% |
Day's Open | 2.38 |
Day's Range | 14.56 - 16.09 |
Day's Volume | 101,708 |
52-Week Range | 0.86 - 16.09 |
News
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to preve...
NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a coll...
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-...
NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or th...
ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and we...
BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...
ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash
The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.
There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.
Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upr...
BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to pre...
TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.
As of late, it has definitely been a great time to be an investor in resTORbio.
About TORC
resTORbio, a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to tr... [Read more...]
Industry Biotechnology | IPO Date Jan 26, 2018 |
CEO Chen Schor | Employees 10 |
Stock Exchange NASDAQ | Ticker Symbol TORC |